Industry views sought on EMA genomic biomarker consultation in drug development
14 July 2011
Vibha Sharma
Please Login to read the full article.
14 July 2011
Vibha Sharma
Please Login to read the full article.
RELATED CONTENT
NEWS
- EU reprieve for Actos as CHMP concludes benefits outweigh risks in selected patients
- In bone drug quandary, FDA seeks panel's advice on safety, 'drug holidays'
- BMS' kidney transplant drug, Nulojix, granted European approval
- EMA confirms Champix' positive benefit-risk balance, but will review data in September
FEATURES
Other Informa Features
